{'fraction_non_alphanumeric': 0.023113528212100613, 'fraction_numerical': 0.01971447994561523, 'mean_word_length': 5.133333333333334, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Annual Review of Advances in Non-small Cell Lung Cancer Research: A Report for the Year 2010

Lung cancer is the leading cause of cancer mortality in the United States and worldwide,1,2 and the prognosis remains poor with an estimated 5-year overall survival (OS) rate of 15%.2 Approximately 85% of the cases of lung cancer are non-small cell lung cancer (NSCLC), and the majority of patients have advanced stage disease at the time of diagnosis.3 Significant investigations into the etiology, molecular characteristics, and the development of novel therapies for NSCLC have been performed and are ongoing. Consequently, NSCLC research and care have evolved into a multidisciplinary approach. As a variety of disciplines perform important research and the results are published in multiple journals, it has become increasingly difficult to remain current on the recent publications. We sought to provide a concise review of the major publications related to lung cancer in the fields of molecularly biology, surgery, radiation oncology, and medical oncology. We restricted the review to clinical trials that were published in peer-reviewed journals to the calendar year of 2010; given the rapid developments within the field of molecular biology, abstracts and presentations from 2010 and early 2011 were included in this review. Unfortunately, no appreciable progress was made in small cell lung cancer in the year 2010; therefore, the focus on the review will be NSCLC.